T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PVLA
2451
Palvella Therapeutics
PVLA
$2.26B
| $429K | ﹤0.01% |
4,090
+433
| +12% | +$36.9K |
|
2452
CNB Financial Corp
CCNE
$1.04B
| $428K | ﹤0.01% |
16,342
+1,495
| +10% | +$37.9K |
|
2453
Conduent
CNDT
$252M
| $427K | ﹤0.01% |
221,895
+12,758
| +6% | +$27.9K |
|
2454
Cadiz
CDZI
$295M
| $426K | ﹤0.01% |
75,920
+6,650
| +10% | +$35.7K |
|
2455
Business First Bancshares
BFST
$1.05B
| $425K | ﹤0.01% |
16,236
+1,268
| +8% | +$32.1K |
|
2456
Porch Group
PRCH
$1.92B
| $425K | ﹤0.01% |
46,491
+2,455
| +6% | +$29.6K |
|
2457
Flexsteel Industries
FLXS
$303M
| $424K | ﹤0.01% |
10,722
| – | – |
|
2458
Designer Brands
DBI
$312M
| $423K | ﹤0.01% |
56,887
+4,988
| +10% | +$24K |
|
2459
Aclaris Therapeutics
ACRS
$863M
| $422K | ﹤0.01% |
140,167
| – | – |
|
2460
Inhibrx
INBX
$1.42B
| $422K | ﹤0.01% |
+5,334
| New | +$363K |
|
2461
Quanex
NX
$981M
| $420K | ﹤0.01% |
27,253
+2,408
| +10% | +$34K |
|
2462
Savara
SVRA
$1.08B
| $420K | ﹤0.01% |
69,536
+2,116
| +3% | +$10.4K |
|
2463
Costamare
CMRE
$1.74B
| $417K | ﹤0.01% |
26,390
+2,958
| +13% | +$40.9K |
|
2464
Esquire Financial Holdings
ESQ
$1.59B
| $417K | ﹤0.01% |
4,084
+350
| +9% | +$35.5K |
|
|
MITT
2465
TPG Mortgage Investment Trust
MITT
$214M
| $415K | ﹤0.01% |
48,655
| – | – |
|
|
FFWM
2466
DELISTED
First Foundation Inc
FFWM
| $414K | ﹤0.01% |
67,155
+33,370
| +99% | +$187K |
|
|
HTBK
2467
DELISTED
Heritage Commerce
HTBK
| $413K | ﹤0.01% |
34,386
+2,885
| +9% | +$31.3K |
|
2468
Nordic American Tanker
NAT
$1.4B
| $413K | ﹤0.01% |
119,792
+11,162
| +10% | +$39.5K |
|
2469
Golub Capital BDC
GBDC
$3.48B
| $412K | ﹤0.01% |
30,323
-17,034
| -36% | -$236K |
|
2470
Geron
GERN
$982M
| $412K | ﹤0.01% |
312,027
+23,189
| +8% | +$29.1K |
|
2471
Lincoln Educational Services
LINC
$955M
| $410K | ﹤0.01% |
16,976
+1,400
| +9% | +$30.5K |
|
2472
Precigen
PGEN
$2.32B
| $410K | ﹤0.01% |
97,938
+18,382
| +23% | +$71.1K |
|
|
CMRC
2473
Commerce.com Inc Series 1
CMRC
$184M
| $409K | ﹤0.01% |
99,209
+2,950
| +3% | +$13.6K |
|
2474
Ranpak Holdings
PACK
$479M
| $408K | ﹤0.01% |
75,272
+33,200
| +79% | +$175K |
|
2475
Royal Bank of Canada
RY
$299B
| $408K | ﹤0.01% |
2,390
-200
| -8% | -$30.7K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.